Compare PRU & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRU | TEVA |
|---|---|---|
| Founded | 1875 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4B | 40.5B |
| IPO Year | 2001 | 1996 |
| Metric | PRU | TEVA |
|---|---|---|
| Price | $124.78 | $36.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $103.71 | $38.63 |
| AVG Volume (30 Days) | 1.7M | ★ 5.5M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | 33.20 | ★ 183.45 |
| EPS | ★ 4.48 | N/A |
| Revenue | ★ $60,774,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | $2.97 |
| P/E Ratio | $27.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $91.89 | $17.33 |
| 52 Week High | $127.72 | $37.39 |
| Indicator | PRU | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 67.70 | 66.67 |
| Support Level | $99.91 | $30.42 |
| Resistance Level | $127.72 | $37.17 |
| Average True Range (ATR) | 2.64 | 1.04 |
| MACD | -0.20 | 0.34 |
| Stochastic Oscillator | 70.37 | 88.48 |
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2025 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 39% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 11% of its 2025 adjusted earnings. PGIM had around $1.47 trillion in assets under management at the end of fourth-quarter 2025.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.